Alcobra Ltd. Ord (ADHD) 4.31 $ADHD
Alcobra Granted European Orphan Drug Designation for Metadoxine in Fragile X Syndrome
GlobeNewswire - Tue Jul 19, 7:00AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that the European Commission (EC) has granted Orphan Drug designation to Metadoxine for the treatment of Fragile X Syndrome within the European Union.
ADHD: 4.31 (+0.03)
Alcobra Ltd. to Participate in Upcoming Investment Conferences
GlobeNewswire - Wed Jun 01, 7:00AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (Fragile X), today announced corporate presentations at the upcoming Jefferies 2016 Healthcare Conference and the ROTH 3 Annual Healthcare Day.
ADHD: 4.31 (+0.03)
Alcobra (ADHD) Catches Eye: Stock Adds 6.3% in Session
Zacks Equity Research - Zacks Investment Research - Fri May 20, 7:30AM CDT
Alcobra Ltd (ADHD) was a big mover last session, as the company saw its shares rise over 6% on the day.
ADHD: 4.31 (+0.03), JNP: 7.50 (-0.04)
The Zacks Analyst Blog Highlights: Alcobra, Editas Medicine, Syndax Pharmaceuticals, Seres Therapeutics and Neos Therapeutics
Zacks Equity Research - Zacks Investment Research - Mon May 16, 8:30AM CDT
The Zacks Analyst Blog Highlights: Alcobra, Editas Medicine, Syndax Pharmaceuticals, Seres Therapeutics and Neos Therapeutics
SNDX: 12.22 (-0.20), EDIT: 25.70 (-0.02), ADHD: 4.31 (+0.03), MCRB: 9.73 (-1.21), NEOS: 8.84 (+0.01)
Alcobra reports 1Q loss
Automated Insights - Mon May 16, 7:15AM CDT
TEL AVIV, Israel (AP) _ Alcobra Ltd. (ADHD) on Monday reported a loss of $5.1 million in its first quarter.
ADHD: 4.31 (+0.03)
Alcobra Announces First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Mon May 16, 7:00AM CDT
-- Conference Call & Webcast May 16th at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time
ADHD: 4.31 (+0.03)
Drug Stocks' Earnings to Watch on May 16: ADHD, MCRB & More
Zacks Equity Research - Zacks Investment Research - Fri May 13, 8:26AM CDT
What's in store for drug stocks, Alcobra, Seres and others when they report their first-quarter results on May 16?
SNDX: 12.22 (-0.20), EDIT: 25.70 (-0.02), ADHD: 4.31 (+0.03), MCRB: 9.73 (-1.21), NEOS: 8.84 (+0.01)
Alcobra Ltd. to Release First Quarter Financial Results and Host Corporate Update Conference Call & Webcast on May 16
GlobeNewswire - Wed May 04, 7:00AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the first quarter ended March 31, 2016 before the market open, and will host a corporate update conference call and webcast on Monday, May 16, at 8:30 am Eastern Time.
ADHD: 4.31 (+0.03)
MEI Pharma (MEIP) in Focus: Stock Rises 7.9% in Session
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 7:35AM CDT
MEI Pharma, Inc. (MEIP) was a big mover last session, as the company saw its shares climb nearly 8% on the day.
ADHD: 4.31 (+0.03), MEIP: 1.47 (+0.11)
Falling Earnings Estimates Signal Weakness Ahead for Valeant Pharmaceuticals (VRX)
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 9:53AM CDT
Valeant Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off
VRX: 20.89 (-1.41), ADHD: 4.31 (+0.03)
Recro Pharma (REPH) Looks Good: Stock Adds 5% in Session
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 7:40AM CDT
Recro Pharma, Inc. (REPH) saw its shares rise 5% in the last trading session.
ADHD: 4.31 (+0.03), REPH: 9.70 (-0.21)
What Falling Estimates & Price Mean for Lannett (LCI)
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 7:40AM CDT
Lannett has an unfavorable Zacks Rank and the stock has been witnessing a significant price decline and negative earnings estimate revisions
LCI: 31.10 (-0.12), ADHD: 4.31 (+0.03)
Alcobra (ADHD) Sees Hammer Chart Pattern: Time to Buy?
Zacks Equity Research - Zacks Investment Research - Fri Apr 01, 5:34AM CDT
Alcobra Ltd. (ADHD) has been struggling lately, but the selling pressure may be coming to an end soon
ADHD: 4.31 (+0.03)
Grab These 4 Incredible Momentum Stocks for Less Than $10
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 9:10AM CDT
Momentum investing grants success to those who can effectively ride the upswing and brave the downswing of the market with the same elan.
PRMW: 11.76 (-0.22), ADHD: 4.31 (+0.03), VSLR: 2.94 (-0.08), MDXG: 7.71 (+0.22)
Ohr Pharmaceutical (OHRP) Worth Watching: Stock Up 16.5%
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 7:00AM CDT
Ohr Pharmaceutical (OHRP) was a big mover last session, with its shares rising roughly 17% on the day.
ADHD: 4.31 (+0.03), OHRP: 2.73 (unch)
AcelRx Pharmaceuticals Names Howard B. Rosen as Chief Executive Officer and Provides Update on Clinical Development Activities and Corporate Priorities for 2016
PR Newswire - Tue Mar 29, 3:00PM CDT
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today the appointment of Howard B. Rosen as the Chief Executive Officer of AcelRx, effective April 1, 2016. Mr. Rosen has served as the interim CEO for AcelRx since April 1, 2015. Mr. Rosen is an experienced and technically trained executive with over 25 years of success growing start-up and mid-size biopharmaceutical companies. Mr. Rosen previously held senior-level general management positions and functional roles in strategy, marketing, finance, business development, and research and development at Gilead Sciences, Inc. and ALZA Corporation. More recently he was interim CEO of Pearl Therapeutics which was subsequently acquired by Astra Zeneca for up to $1.15 billion in 2013. Mr. Rosen has served on the Board of Directors of AcelRx since 2008 and currently serves on the Board of Directors of Alcobra, Ltd. and two private biopharmaceutical companies.
ACRX: 3.48 (-0.15), GILD: 80.46 (+0.99), ADHD: 4.31 (+0.03)
Synergy Pharmaceuticals (SGYP) Jumps: Stock Gains 6.1%
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 7:00AM CDT
Synergy Pharmaceuticals (SGYP) was a big mover last session, with its shares rising over 6% on the day.
SGYP: 4.13 (+0.05), ADHD: 4.31 (+0.03)
Weakness Seen in Anacor Pharmaceuticals (ANAC) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Fri Mar 18, 8:00AM CDT
Anacor Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off
ADHD: 4.31 (+0.03), ANAC: 99.06 (-0.14)
What's in Store for Penumbra (PEN) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 12:20PM CST
Penumbra, Inc. (PEN) is expected to report its fourth-quarter and full year 2015 financial numbers on Feb 11, after the market close.
VWR: 31.31 (-0.01), ADHD: 4.31 (+0.03), PEN: 68.53 (+0.22), MGLN: 65.72 (-2.75)
GNC Holdings (GNC) Q4 Earnings: A Turnaround in Store?
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 11:50AM CST
The combination of GNC Holdings' (GNC) Zacks Rank #3 and +1.67% ESP makes us confident of a positive earnings beat at the company.
CNC: 69.44 (-1.11), ADHD: 4.31 (+0.03), GNC: 19.97 (-0.44), MGLN: 65.72 (-2.75)
Alcobra Granted European Orphan Drug Designation for Metadoxine in Fragile X Syndrome
GlobeNewswire - Tue Jul 19, 7:00AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that the European Commission (EC) has granted Orphan Drug designation to Metadoxine for the treatment of Fragile X Syndrome within the European Union.
ADHD: 4.31 (+0.03)
Alcobra Ltd. to Participate in Upcoming Investment Conferences
GlobeNewswire - Wed Jun 01, 7:00AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (Fragile X), today announced corporate presentations at the upcoming Jefferies 2016 Healthcare Conference and the ROTH 3 Annual Healthcare Day.
ADHD: 4.31 (+0.03)
Alcobra (ADHD) Catches Eye: Stock Adds 6.3% in Session
Zacks Equity Research - Zacks Investment Research - Fri May 20, 7:30AM CDT
Alcobra Ltd (ADHD) was a big mover last session, as the company saw its shares rise over 6% on the day.
ADHD: 4.31 (+0.03), JNP: 7.50 (-0.04)
The Zacks Analyst Blog Highlights: Alcobra, Editas Medicine, Syndax Pharmaceuticals, Seres Therapeutics and Neos Therapeutics
Zacks Equity Research - Zacks Investment Research - Mon May 16, 8:30AM CDT
The Zacks Analyst Blog Highlights: Alcobra, Editas Medicine, Syndax Pharmaceuticals, Seres Therapeutics and Neos Therapeutics
SNDX: 12.22 (-0.20), EDIT: 25.70 (-0.02), ADHD: 4.31 (+0.03), MCRB: 9.73 (-1.21), NEOS: 8.84 (+0.01)
Alcobra reports 1Q loss
Automated Insights - Mon May 16, 7:15AM CDT
TEL AVIV, Israel (AP) _ Alcobra Ltd. (ADHD) on Monday reported a loss of $5.1 million in its first quarter.
ADHD: 4.31 (+0.03)
Alcobra Announces First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Mon May 16, 7:00AM CDT
-- Conference Call & Webcast May 16th at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time
ADHD: 4.31 (+0.03)
Drug Stocks' Earnings to Watch on May 16: ADHD, MCRB & More
Zacks Equity Research - Zacks Investment Research - Fri May 13, 8:26AM CDT
What's in store for drug stocks, Alcobra, Seres and others when they report their first-quarter results on May 16?
SNDX: 12.22 (-0.20), EDIT: 25.70 (-0.02), ADHD: 4.31 (+0.03), MCRB: 9.73 (-1.21), NEOS: 8.84 (+0.01)
Alcobra Ltd. to Release First Quarter Financial Results and Host Corporate Update Conference Call & Webcast on May 16
GlobeNewswire - Wed May 04, 7:00AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the first quarter ended March 31, 2016 before the market open, and will host a corporate update conference call and webcast on Monday, May 16, at 8:30 am Eastern Time.
ADHD: 4.31 (+0.03)
MEI Pharma (MEIP) in Focus: Stock Rises 7.9% in Session
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 7:35AM CDT
MEI Pharma, Inc. (MEIP) was a big mover last session, as the company saw its shares climb nearly 8% on the day.
ADHD: 4.31 (+0.03), MEIP: 1.47 (+0.11)
Falling Earnings Estimates Signal Weakness Ahead for Valeant Pharmaceuticals (VRX)
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 9:53AM CDT
Valeant Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off
VRX: 20.89 (-1.41), ADHD: 4.31 (+0.03)
Recro Pharma (REPH) Looks Good: Stock Adds 5% in Session
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 7:40AM CDT
Recro Pharma, Inc. (REPH) saw its shares rise 5% in the last trading session.
ADHD: 4.31 (+0.03), REPH: 9.70 (-0.21)
What Falling Estimates & Price Mean for Lannett (LCI)
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 7:40AM CDT
Lannett has an unfavorable Zacks Rank and the stock has been witnessing a significant price decline and negative earnings estimate revisions
LCI: 31.10 (-0.12), ADHD: 4.31 (+0.03)
Alcobra (ADHD) Sees Hammer Chart Pattern: Time to Buy?
Zacks Equity Research - Zacks Investment Research - Fri Apr 01, 5:34AM CDT
Alcobra Ltd. (ADHD) has been struggling lately, but the selling pressure may be coming to an end soon
ADHD: 4.31 (+0.03)
Grab These 4 Incredible Momentum Stocks for Less Than $10
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 9:10AM CDT
Momentum investing grants success to those who can effectively ride the upswing and brave the downswing of the market with the same elan.
PRMW: 11.76 (-0.22), ADHD: 4.31 (+0.03), VSLR: 2.94 (-0.08), MDXG: 7.71 (+0.22)
Ohr Pharmaceutical (OHRP) Worth Watching: Stock Up 16.5%
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 7:00AM CDT
Ohr Pharmaceutical (OHRP) was a big mover last session, with its shares rising roughly 17% on the day.
ADHD: 4.31 (+0.03), OHRP: 2.73 (unch)
AcelRx Pharmaceuticals Names Howard B. Rosen as Chief Executive Officer and Provides Update on Clinical Development Activities and Corporate Priorities for 2016
PR Newswire - Tue Mar 29, 3:00PM CDT
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today the appointment of Howard B. Rosen as the Chief Executive Officer of AcelRx, effective April 1, 2016. Mr. Rosen has served as the interim CEO for AcelRx since April 1, 2015. Mr. Rosen is an experienced and technically trained executive with over 25 years of success growing start-up and mid-size biopharmaceutical companies. Mr. Rosen previously held senior-level general management positions and functional roles in strategy, marketing, finance, business development, and research and development at Gilead Sciences, Inc. and ALZA Corporation. More recently he was interim CEO of Pearl Therapeutics which was subsequently acquired by Astra Zeneca for up to $1.15 billion in 2013. Mr. Rosen has served on the Board of Directors of AcelRx since 2008 and currently serves on the Board of Directors of Alcobra, Ltd. and two private biopharmaceutical companies.
ACRX: 3.48 (-0.15), GILD: 80.46 (+0.99), ADHD: 4.31 (+0.03)
Synergy Pharmaceuticals (SGYP) Jumps: Stock Gains 6.1%
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 7:00AM CDT
Synergy Pharmaceuticals (SGYP) was a big mover last session, with its shares rising over 6% on the day.
SGYP: 4.13 (+0.05), ADHD: 4.31 (+0.03)
Weakness Seen in Anacor Pharmaceuticals (ANAC) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Fri Mar 18, 8:00AM CDT
Anacor Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off
ADHD: 4.31 (+0.03), ANAC: 99.06 (-0.14)
What's in Store for Penumbra (PEN) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 12:20PM CST
Penumbra, Inc. (PEN) is expected to report its fourth-quarter and full year 2015 financial numbers on Feb 11, after the market close.
VWR: 31.31 (-0.01), ADHD: 4.31 (+0.03), PEN: 68.53 (+0.22), MGLN: 65.72 (-2.75)
GNC Holdings (GNC) Q4 Earnings: A Turnaround in Store?
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 11:50AM CST
The combination of GNC Holdings' (GNC) Zacks Rank #3 and +1.67% ESP makes us confident of a positive earnings beat at the company.
CNC: 69.44 (-1.11), ADHD: 4.31 (+0.03), GNC: 19.97 (-0.44), MGLN: 65.72 (-2.75)
